Engineered Nanoparticles for Drug Delivery in Cancer Therapy
The DOI matches its Crossref record; 579 of the 579 references it cites were found in a registry or an index.
Abstract
In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a number of issues associated with conventional therapeutic agents, including their poor water solubility (at least, for most anticancer drugs), lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic index. Over the past several decades, remarkable progress has been made in the development and application of engineered nanoparticles to treat cancer more effectively. For example, therapeutic agents have been integrated with nanoparticles engineered with optimal sizes, shapes, and surface properties to increase their solubility, prolong their circulation half‐life, improve their biodistribution, and reduce their immunogenicity. Nanoparticles and their payloads have also been favorably delivered into tumors by taking advantage of the pathophysiological conditions, such as the enhanced permeability and retention effect, and the spatial variations in the pH value. Additionally, targeting ligands (e.g., small organic molecules, peptides, antibodies, and nucleic acids) have been added to the surface of nanoparticles to specifically target cancerous cells through selective binding to the receptors overexpressed on their surface. Furthermore, it has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contrast agents) could be delivered through the same carrier to enable combination therapy with a potential to overcome multidrug resistance, and real‐time readout on the treatment efficacy. It is anticipated that precisely engineered nanoparticles will emerge as the next‐generation platform for cancer therapy and many other biomedical applications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
In the citing paper
“Vasculature plays an essential role in the growth and metastasis of malignant tumors [103].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
Citations
Cites
Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism
Kresge, C. T., Leonowicz, M. E., Roth, W. J., Vartuli, J. C., & Beck, J. S. (1992) · Nature · doi:10.1038/359710a0 · Cited by 16,275
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Chemistry and Properties of Nanocrystals of Different Shapes
Burda, C., Chen, X., Narayanan, R., & El-Sayed, M. A. (2005) · Chemical Reviews · doi:10.1021/cr030063a · Cited by 7,230
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Research works printed but not linked: 29
- Aruna U., 2013, Inter. J. Inn. Pharm. Res., 4, 318
- Langer R., 1998, Nature, 392, 5
- Petre C. E., 2007, Int. J. Nanomed., 2, 277
- Lao J., 2013, J. Drug Delivery, 456409
- Saif M. W., 2007, JOP, 8, 166
- Matsumura Y., 1986, Cancer Res., 46, 6387
- Xu G., 2001, Clin. Cancer Res., 7, 3314
- 10.1016/j.addr.2012.09.008 · doi:10.1016/j.addr.2012.09.008 · Paper page
- Pundir S., 2013, Int. J. Drug Res. Technol., 3, 12
- 10.1021/jp077468 · doi:10.1021/jp077468
- Mohanraj V. J., 2006, J. Pharm. Res., 5, 561
- Ma Y. D., 2011, Int. J. Nanomed., 6, 2679
- 10.1002/(SICI)1097-4636(199908)46:2<236::AID-JBM13>3.0.CO;2-F · doi:10.1002/(sici)1097-4636(199908)46:2<236::aid-jbm13>3.0.co;2-f
- Krishna R., 2000, Eur. J. Cancer Sci., 11, 265
- Kettiger H., 2013, Int. J. Nanomed., 8, 3255
- Yuan F., 1995, Cancer Res., 55, 3752
- Jain R. K., 1987, Cancer Res., 47, 3039
- 10.1021/nn900002m · DOI · Paper page
- Chidambaram M., 2012, Int. J. Pharm. Sci., 2, 117
- 10.1039/C1CS15237H · DOI · Paper page
- 10.1038/nnano.2007.223 · DOI · Paper page
- Mohanraj V. J., 2006, Trop. J. Pharm. Res., 5, 561
- Hong R. L., 1999, Clin. Cancer Res., 5, 3645
- Shamsipour F., 2009, Avicenna J. Med. Biotechnol., 1, 27
- Park J. W., 2002, Clin. Cancer Res., 8, 1172
- Uppada S. B., 2014, Int. J. Nanomed., 9, 43
- Bangham A. D., 1965, J. Mol. Biol., 13, 227
- Mueller C., 1994, Methods Cell Sci., 16, 183
- 10.1016/j.cbpa.2005.10.005 · DOI
Cited by
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors
Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s146315 · Cited by 1,577
“A number of nanocarrier-based products have been approved for the treatment of various tumors, and many others are in different phases of clinical trials.(4) In the current review, we first discussed features of different types of nanocarriers (organic, inorganic and hybrid) along with their relevance in cancer therap…”
BackgroundInfluentialLiposomes: Structure, composition, types, and clinical applications
Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09394 · Cited by 1,561
“Liposomes are spherical lipid vesicles (usually 50–500 nm in diameter particle size) composed of one or more lipid bilayers, as a result of emulsifying natural or synthetic lipids in an aqueous medium [12, 13] (Figure 1).”
BackgroundNanoparticle–liver interactions: Cellular uptake and hepatobiliary elimination
Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D., & Chan, W. C. W. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.020 · Cited by 1,349
“020 intended target and are sequestered by the liver and spleen (if N6 nm) or eliminated though the kidney (if b6 nm) after administration into the body [2,4].”
BackgroundMethodSelf-citationChallenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Gold Nanomaterials at Work in Biomedicine
Yang, X., Yang, M., Pang, B., Vara, M., & Xia, Y. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00193 · Cited by 1,162
Self-citationA review on nanoparticles: characteristics, synthesis, applications, and challenges
Altammar, K. A. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1155622 · Cited by 1,067
“The particles can be used in biomedical applications such as cancer treatment (Sun et al., 2014), biological imaging (Abdulle and Chow, 2019), chemical sensing, and drug delivery.”
BackgroundMetal–Organic Frameworks for Biomedical Applications
Yang, J., & Yang, Y. (2020) · Small · doi:10.1002/smll.201906846 · Cited by 998
Cancer nanomedicine: A review of recent success in drug delivery
Tran, S., DeGiovanni, P., Piel, B., & Rai, P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0175-0 · Cited by 879
“the scheme of cores and branching units, the molecular weight, size, branch density, flexibility, and water solubility can be specified [49].”
BackgroundInfluentialInnovative approaches for cancer treatment: current perspectives and new challenges
Pucci, C., Martinelli, C., & Ciofani, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.961 · Cited by 814
Nanocomposite Hydrogels: 3D Polymer–Nanoparticle Synergies for On-Demand Drug Delivery
Merino, S., Martín, C., Kostarelos, K., Prato, M., & Vázquez, E. (2015) · ACS Nano · doi:10.1021/acsnano.5b01433 · Cited by 801
“as advanced systems with the promise of delivering drugs to target cells, especially in cancer therapy.(2) However, clinical applica-”
BackgroundImidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model
Zhang, Y., Tan, H., Daniels, J. D., Zandkarimi, F., Liu, H., Brown, L. M., Uchida, K., O'Connor, O. A., & Stockwell, B. R. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.01.008 · Cited by 721
“However, IKE NP-treated mice had a similar weight compared with the saline vehicle and the NP vehicle groups; the lower toxicity of the IKE NP formulation might result from the NPs’ capability to prevent the aggregation of hydrophobic drugs (Sun et al., 2014), or the NP EPR effect, which decreases the non-specific dis…”
BackgroundSelf-citationZhou, J., Yu, G., & Huang, F. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00898d · Cited by 677
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
Yang, M., Li, J., Gu, P., & Fan, X. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.12.010 · Cited by 670
“As the efficacy of traditional anti-tumor drugs, such as chemotherapeutic or immunomodulatory agents, has been restricted by the ECM barriers which limit the diffusion of drugs [71], CAF-targeted nanoparticles used in remodeling TME have attracted great attention (Table 1).”
BackgroundSelf-citationCurrent trends and challenges in cancer management and therapy using designer nanomaterials
Navya, P. N., Kaphle, A., Srinivas, S. P., Bhargava, S. K., Rotello, V. M., & Daima, H. K. (2019) · Nano Convergence · doi:10.1186/s40580-019-0193-2 · Cited by 672
“Additionally, the size and shape of the nanomaterials impact the drug loading and release, along with the stability [102].”
BackgroundLi, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
“Examples of NPs include polymers, solid lipids, metals, quantum dots, dendrimers, liposomes, and micelles (BarZeev et al., 2016; Livney and Assaraf, 2013; Shapira et al., 2012; Sun et al., 2014; Yang et al., 2016; Zhang and Akbulut, 2011).”
BackgroundQuantifying the Ligand-Coated Nanoparticle Delivery to Cancer Cells in Solid Tumors
Dai, Q., Wilhelm, S., Ding, D., Syed, A. M., Sindhwani, S., Zhang, Y., Chen, Y. Y., MacMillan, P., & Chan, W. C. W. (2018) · ACS Nano · doi:10.1021/acsnano.8b03900 · Cited by 658
Self-citationTransport and interactions of nanoparticles in the kidneys
Du, B., Yu, M., & Zheng, J. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0038-3 · Cited by 649
Feng, T., Ai, X., An, G., Yang, P., & Zhao, Y. (2016) · ACS Nano · doi:10.1021/acsnano.6b00043 · Cited by 650
Elmowafy, E. M., Tiboni, M., & Soliman, M. E. (2019) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-019-00439-x · Cited by 621
“Several systems based on PLA or PLGA have been prepared to deliver different payloads ranging from small drug molecules to large proteins and nucleic acids in a sustained release manner (Sun et al. 2014).”
BackgroundNanoparticle decoration with surfactants: Molecular interactions, assembly, and applications
Heinz, H., Pramanik, C., Heinz, O., Ding, Y., Mishra, R. K., Marchon, D., Flatt, R. J., Estrela-Lopis, I., Llop, J., Moya, S., et al. (2017) · Surface Science Reports · doi:10.1016/j.surfrep.2017.02.001 · Cited by 608
Transformable liquid-metal nanomedicine
Lu, Y., Hu, Q., Lin, Y., Pacardo, D. B., Wang, C., Sun, W., Ligler, F. S., Dickey, M. D., & Gu, Z. (2015) · Nature Communications · doi:10.1038/ncomms10066 · Cited by 593
Zhang, L., Wan, S.-S., Li, C.-X., Xu, L., Cheng, H., & Zhang, X.-Z. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b03178 · Cited by 584
Drug self-delivery systems for cancer therapy
Qin, S.-Y., Zhang, A.-Q., Cheng, S.-X., Rong, L., & Zhang, X.-Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.10.016 · Cited by 532
Moradi Kashkooli, F., Soltani, M., & Souri, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.012 · Cited by 514
Jia, Q., Ge, J., Liu, W., Zheng, X., Chen, S., Wen, Y., Zhang, H., & Wang, P. (2018) · Advanced Materials · doi:10.1002/adma.201706090 · Cited by 509
Silver-Based Plasmonic Nanoparticles for and Their Use in Biosensing
Loiseau, A., Asila, V., Boitel-Aullen, G., Lam, M., Salmain, M., & Boujday, S. (2019) · Biosensors · doi:10.3390/bios9020078 · Cited by 503
“Another polymer, called chitosan, is widely used to coat NPs because of its good biocompatibility [131,132].”
BackgroundMenichetti, A., Mavridi-Printezi, A., Mordini, D., & Montalti, M. (2023) · Journal of Functional Biomaterials · doi:10.3390/jfb14050244 · Cited by 502
“Additional beneficial characteristics of nanoparticles’ application in the biomedical field include biocompatibility [28,29], specific target recognition [24] and the ability to functionalize the surface and use them as carriers for drug delivery [30,31].”
BackgroundThe Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Cellular Uptake of Nanoparticles versus Small Molecules: A Matter of Size
Mosquera, J., García, I., & Liz-Marzán, L. M. (2018) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00292 · Cited by 487
Recent Advances in Cell Membrane–Camouflaged Nanoparticles for Cancer Phototherapy
Zhen, X., Cheng, P., & Pu, K. (2019) · Small · doi:10.1002/smll.201804105 · Cited by 483
Nanocarriers for drug delivery applications
Chamundeeswari, M., Jeslin, J., & Verma, M. L. (2019) · Environmental Chemistry Letters · doi:10.1007/s10311-018-00841-1 · Cited by 444
Gold nanoparticles for cancer radiotherapy: a review
Haume, K., Rosa, S., Grellet, S., Śmiałek, M. A., Butterworth, K. T., Solov’yov, A. V., Prise, K. M., Golding, J., & Mason, N. J. (2016) · Cancer Nanotechnology · doi:10.1186/s12645-016-0021-x · Cited by 445
“In addition to the use of NPs in nanomedicine, which has successfully improved the specificity of modern chemotherapeutics in recent years (Ranganathan et al. 2012; Danhier et al. 2010; Sun et al. 2014), promising demonstrations of the radiosensitising potential of NPs in the last decade, both in vitro and in vivo, no…”
The glycocalyx and its significance in human medicine
Tarbell, J. M., & Cancel, L. M. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12465 · Cited by 440
Degradability and Clearance of Inorganic Nanoparticles for Biomedical Applications
Yang, G., Phua, S. Z. F., Bindra, A. K., & Zhao, Y. (2019) · Advanced Materials · doi:10.1002/adma.201805730 · Cited by 436
Light-Triggered Drug Release from 3D-Printed Magnetic Chitosan Microswimmers
Bozuyuk, U., Yasa, O., Yasa, I. C., Ceylan, H., Kizilel, S., & Sitti, M. (2018) · ACS Nano · doi:10.1021/acsnano.8b05997 · Cited by 422
Cancer Nanotechnology: A New Revolution for Cancer Diagnosis and Therapy
Chaturvedi, V. K., Singh, A., Singh, V. K., & Singh, M. P. (2019) · Current Drug Metabolism · doi:10.2174/1389200219666180918111528 · Cited by 418
Application of Light Scattering Techniques to Nanoparticle Characterization and Development
Carvalho, P. M., Felício, M. R., Santos, N. C., Gonçalves, S., & Domingues, M. M. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00237 · Cited by 402
“With nanoparticles activity being dependent of their physicochemical properties, namely size, shape, and surface, their toxicity toward cells is also dependent of these properties (Bera et al., 2014; Sun et al., 2014; Rajchakit and Sarojini, 2017).”
BackgroundChiangjong, W., Chutipongtanate, S., & Hongeng, S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5099 · Cited by 388
“However, drug binding adjuvant and nanoparticles can retain drug concentration during transport to target areas and induce the slow-release of the drug at these target areas (100,101).”
Niu, W., Xiao, Q., Wang, X., Zhu, J., Li, J., Liang, X., Peng, Y., Wu, C., Lu, R., Pan, Y., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.0c04753 · Cited by 372
Xiong, Y., Lin, Z., Bu, P., Yu, T., Endo, Y., Zhou, W., Sun, Y., Cao, F., Dai, G., Hu, Y., et al. (2023) · Advanced Materials · doi:10.1002/adma.202212300 · Cited by 370
Coaxial Electrospinning Formation of Complex Polymer Fibers and their Applications
Han, D., & Steckl, A. J. (2019) · ChemPlusChem · doi:10.1002/cplu.201900281 · Cited by 355
Advanced bioactive nanomaterials for biomedical applications
Zhao, Y., Zhang, Z., Pan, Z., & Liu, Y. (2021) · Exploration · doi:10.1002/exp.20210089 · Cited by 357
Aggregation-Induced Emission: A Trailblazing Journey to the Field of Biomedicine
Zhu, C., Kwok, R. T. K., Lam, J. W. Y., & Tang, B. Z. (2018) · ACS Applied Bio Materials · doi:10.1021/acsabm.8b00600 · Cited by 343
Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs
Bayón-Cordero, L., Alkorta, I., & Arana, L. (2019) · Nanomaterials · doi:10.3390/nano9030474 · Cited by 344
“This effect is mainly based in the fast angiogenesis carried out by solid tumors to maintain enough supplies of oxygen and nutrients [31].”
BackgroundInfluentialNanotechnology in healthcare, and its safety and environmental risks
Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L. W., Chang, J., Williams, G., Knowles, J. C., & Poma, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02901-x · Cited by 332
Advanced optoacoustic methods for multiscale imaging of in vivo dynamics
Deán-Ben, X. L., Gottschalk, S., Mc Larney, B., Shoham, S., & Razansky, D. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00765a · Cited by 337
Protein Nanoparticles: Promising Platforms for Drug Delivery Applications
Jain, A., Singh, S. K., Arya, S. K., Kundu, S. C., & Kapoor, S. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b01098 · Cited by 308
Cong, M., Tan, S., Li, S., Gao, L., Huang, L., Zhang, H.-G., & Qiao, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114108 · Cited by 302
Nanoparticles in Clinical Translation for Cancer Therapy
Mundekkad, D., & Cho, W. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031685 · Cited by 305
“placed them in a good position in cancer therapy, especially in ovarian, breast, and non-small cell lung cancers [3].”
BackgroundEnvironmental Impact of Nanoparticles’ Application as an Emerging Technology: A Review
Martínez, G., Merinero, M., Pérez-Aranda, M., Pérez-Soriano, E., Ortiz, T., Villamor, E., Begines, B., & Alcudia, A. (2020) · Materials · doi:10.3390/ma14010166 · Cited by 303
“The possibility of transporting different substances at once granted by nanomaterials is a stimulating advantage and a potential solution for multiple therapies [20].”
BackgroundSynthesis of Self-Assembled Porphyrin Nanoparticle Photosensitizers
Wang, D., Niu, L., Qiao, Z.-Y., Cheng, D.-B., Wang, J., Zhong, Y., Bai, F., Wang, H., & Fan, H. (2018) · ACS Nano · doi:10.1021/acsnano.8b01010 · Cited by 303
Sonodynamic therapy (SDT): a novel strategy for cancer nanotheranostics
Pan, X., Wang, H., Wang, S., Sun, X., Wang, L., Wang, W., Shen, H., & Liu, H. (2018) · Science China Life Sciences · doi:10.1007/s11427-017-9262-x · Cited by 302
Liu, B., Li, C., Yang, P., Hou, Z., & Lin, J. (2017) · Advanced Materials · doi:10.1002/adma.201605434 · Cited by 302
De, R., Mahata, M. K., & Kim, K. (2022) · Advanced Science · doi:10.1002/advs.202105373 · Cited by 297
Immunological Approaches Towards Cancer and Inflammation: A Cross Talk
Qu, X., Tang, Y., & Hua, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00563 · Cited by 301
“Owing to rapid clearance, anticancer drugs are eliminated before showing sufficient intended therapeutic action, while poor accumulation in cancerous tissue and distribution to non-cancerous tissues is associated with high toxicity (149).”
BackgroundPaclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3687700 · Cited by 298
“Chemotherapy by traditional drug administration is the most common cancer treatment, but it involves several issues, including low drug solubility, low precision, high toxicity, and low therapy index [113, 151].”
BackgroundConstruction of Bio‐Piezoelectric Platforms: From Structures and Synthesis to Applications
Xu, Q., Gao, X., Zhao, S., Liu, Y., Zhang, D., Zhou, K., Khanbareh, H., Chen, W., Zhang, Y., & Bowen, C. (2021) · Advanced Materials · doi:10.1002/adma.202008452 · Cited by 298
Self-citationAnticancer Properties of Essential Oils and Other Natural Products
Blowman, K., Magalhães, M., Lemos, M. F. L., Cabral, C., & Pires, I. M. (2018) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2018/3149362 · Cited by 296
“Crucially, EOs can be degraded through physical, chemical, or enzymatic processes, so microsphere encapsulation may prevent this for optimised delivery [88, 89].”
BackgroundBioactive Glass Nanoparticles: From Synthesis to Materials Design for Biomedical Applications
Vichery, C., & Nedelec, J.-M. (2016) · Materials · doi:10.3390/ma9040288 · Cited by 296
“Particles specific accumulation into tumor tissues is called the Enhanced Permeability and Retention (EPR) effect, and lays on the presence of openings of 100–800 nm in tumor vasculature [40].”
BackgroundPark, S. J. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s254808 · Cited by 293
“NPs have been developed as carriers for the delivery of various molecules such as growth factors, genes, antibacterial agents, anti-inflammatory agents, and antibodies.(2,11,12) The use of nanomaterials and carbon nanotubes (CNTs) as drug carriers has increased greatly but their use faces some technical limitations.”
BackgroundLv, S., Wu, Y., Cai, K., He, H., Li, Y., Lan, M., Chen, X., Cheng, J., & Yin, L. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b12776 · Cited by 293
The Promise of Nanotechnology in Personalized Medicine
Alghamdi, M. A., Fallica, A. N., Virzì, N., Kesharwani, P., Pittalà, V., & Greish, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050673 · Cited by 284
“On the other hand, hydrophilic drugs such as proteins and nucleic acids cannot be uptaken by simple passive diffusion by cells because of their incapacity to cross the cell membrane and could suffer poor stability in the aqueous environment [151].”
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 289
Evolution and clinical translation of drug delivery nanomaterials
Hassan, S., Prakash, G., Bal Ozturk, A., Saghazadeh, S., Farhan Sohail, M., Seo, J., Remzi Dokmeci, M., Zhang, Y. S., & Khademhosseini, A. (2017) · Nano Today · doi:10.1016/j.nantod.2017.06.008 · Cited by 288
Self-citationSupercritical Fluid Technology: An Emphasis on Drug Delivery and Related Biomedical Applications
Kankala, R. K., Zhang, Y. S., Wang, S., Lee, C., & Chen, A. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700433 · Cited by 285
Self-citationChiang, C.-S., Lin, Y.-J., Lee, R., Lai, Y.-H., Cheng, H.-W., Hsieh, C.-H., Shyu, W.-C., & Chen, S.-Y. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0146-7 · Cited by 283
Cancer Cell Membrane-Coated Nanoparticles for Cancer Management
Harris, J. C., Scully, M. A., & Day, E. S. (2019) · Cancers · doi:10.3390/cancers11121836 · Cited by 278
“Despite being the main clinical strategy, cytotoxic chemotherapeutics are incapable of targeting only cancer cells post-systemic administration [3,4].”
BackgroundInfluentialMitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Jin, P., Jiang, J., Zhou, L., Huang, Z., Nice, E. C., Huang, C., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01313-4 · Cited by 273
ROS-induced NO generation for gas therapy and sensitizing photodynamic therapy of tumor
Wan, S.-S., Zeng, J.-Y., Cheng, H., & Zhang, X.-Z. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.004 · Cited by 272
Plant-Derived Exosome-Like Nanovesicles: Current Progress and Prospects
Mu, N., Li, J., Zeng, L., You, J., Li, R., Qin, A., Liu, X., Yan, F., & Zhou, Z. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s420748 · Cited by 265
“PELNs have been shown to cross various physiological barriers, including the blood-brain barrier, through receptormediated cellular transport and membrane fusion.(109) In one study, ELNs extracted from grapefruit were loaded with the anti-tumor drug doxorubicin onto heparin-based nanoparticles for glioma treatment.”
BackgroundMontalti, M., Cantelli, A., & Battistelli, G. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00486h · Cited by 265
Supramolecular Photothermal Nanomaterials as an Emerging Paradigm toward Precision Cancer Therapy
Zhao, L., Liu, Y., Chang, R., Xing, R., & Yan, X. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201806877 · Cited by 263
Zhao, X., Yang, K., Zhao, R., Ji, T., Wang, X., Yang, X., Zhang, Y., Cheng, K., Liu, S., Hao, J., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.032 · Cited by 256
Self-citationSong, Q., Yin, Y., Shang, L., Wu, T., Zhang, D., Kong, M., Zhao, Y., He, Y., Tan, S., Guo, Y., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03186 · Cited by 254
Wu, W., Luo, L., Wang, Y., Wu, Q., Dai, H.-B., Li, J.-S., Durkan, C., Wang, N., & Wang, G.-X. (2018) · Theranostics · doi:10.7150/thno.23459 · Cited by 246
“Although pH-responsive [6, 92-102] and size-related [1, 20, 83, 103, 104] antitumor studies have been amply discussed in previous review articles, there is a need to review several aspects of endogenous pH-responsive nanocarriers for antitumor therapy.”
BackgroundPharmapolymers in the 21st century: Synthetic polymers in drug delivery applications
Englert, C., Brendel, J. C., Majdanski, T. C., Yildirim, T., Schubert, S., Gottschaldt, M., Windhab, N., & Schubert, U. S. (2018) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2018.07.005 · Cited by 247
Nanocarriers and Their Loading Strategies
Wang, N., Cheng, X., Li, N., Wang, H., & Chen, H. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801002 · Cited by 245
Surface Charge Controls the Suborgan Biodistributions of Gold Nanoparticles
Elci, S. G., Jiang, Y., Yan, B., Kim, S. T., Saha, K., Moyano, D. F., Yesilbag Tonga, G., Jackson, L. C., Rotello, V. M., & Vachet, R. W. (2016) · ACS Nano · doi:10.1021/acsnano.6b02086 · Cited by 241
Cancer Cell Membrane‐Biomimetic Oxygen Nanocarrier for Breaking Hypoxia‐Induced Chemoresistance
Tian, H., Luo, Z., Liu, L., Zheng, M., Chen, Z., Ma, A., Liang, R., Han, Z., Lu, C., & Cai, L. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201703197 · Cited by 243
From Marine Origin to Therapeutics: The Antitumor Potential of Marine Algae-Derived Compounds
Alves, C., Silva, J., Pinteus, S., Gaspar, H., Alpoim, M. C., Botana, L. M., & Pedrosa, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00777 · Cited by 241
Hu, G., Guo, M., Xu, J., Wu, F., Fan, J., Huang, Q., Yang, G., Lv, Z., Wang, X., & Jin, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01998 · Cited by 237
“Additionally, therapeutic agents loaded into NPs must be designed with optimal sizes, shapes, and surface properties to improve their biodistribution, increase their solubility, enhance their stability, and reduce their immunogenicity (19).”
BackgroundPhotothermally Triggered Copper Payload Release for Cuproptosis‐Promoted Cancer Synergistic Therapy
Zhou, J., Yu, Q., Song, J., Li, S., Li, X., Kang, B., Chen, H., & Xu, J. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202213922 · Cited by 225
Microfluidics‐based 3D cell culture models: Utility in novel drug discovery and delivery research
Gupta, N., Liu, J. R., Patel, B., Solomon, D. E., Vaidya, B., & Gupta, V. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10013 · Cited by 236
Phase‐Change Materials for Controlled Release and Related Applications
Qiu, J., Huo, D., & Xia, Y. (2020) · Advanced Materials · doi:10.1002/adma.202000660 · Cited by 235
Wang, H., Di, J., Sun, Y., Fu, J., Wei, Z., Matsui, H., del C. Alonso, A., & Zhou, S. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201501524 · Cited by 232
Shen, S., Zhu, C., Huo, D., Yang, M., Xue, J., & Xia, Y. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201702898 · Cited by 229
Self-citationGold nanoparticles in combinatorial cancer therapy strategies
Beik, J., Khateri, M., Khosravi, Z., Kamrava, S. K., Kooranifar, S., Ghaznavi, H., & Shakeri-Zadeh, A. (2019) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2019.02.025 · Cited by 229
Boosting Cancer Therapy with Organelle-Targeted Nanomaterials
Gao, P., Pan, W., Li, N., & Tang, B. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b01370 · Cited by 230
Nanostructured carriers as innovative tools for cancer diagnosis and therapy
Martinelli, C., Pucci, C., & Ciofani, G. (2019) · APL Bioengineering · doi:10.1063/1.5079943 · Cited by 228
Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
Shang, M., Soon, R. H., Lim, C. T., Khoo, B. L., & Han, J. (2019) · Lab on a Chip · doi:10.1039/c8lc00970h · Cited by 227
Intracellular Delivery of Functional Proteins and Native Drugs by Cell-Penetrating Poly(disulfide)s
Fu, J., Yu, C., Li, L., & Yao, S. Q. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b08130 · Cited by 225
Jiang, Z., Han, X., Zhao, C., Wang, S., & Tang, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031923 · Cited by 223
“Platinum NPs/graphene oxide Carbon-based nanomaterials Protein Cancer cell detection [20]”
Core–Shell Gold Nanorod@Metal–Organic Framework Nanoprobes for Multimodality Diagnosis of Glioma
Shang, W., Zeng, C., Du, Y., Hui, H., Liang, X., Chi, C., Wang, K., Wang, Z., & Tian, J. (2017) · Advanced Materials · doi:10.1002/adma.201604381 · Cited by 222
Zhang, Y., Wang, F., Li, M., Yu, Z., Qi, R., Ding, J., Zhang, Z., & Chen, X. (2018) · Advanced Science · doi:10.1002/advs.201700821 · Cited by 215
Self-citationAl Sharabati, M., Sabouni, R., & Husseini, G. A. (2022) · Nanomaterials · doi:10.3390/nano12020277 · Cited by 218
Durfee, P. N., Lin, Y.-S., Dunphy, D. R., Muñiz, A. J., Butler, K. S., Humphrey, K. R., Lokke, A. J., Agola, J. O., Chou, S. S., Chen, I.-M., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b02819 · Cited by 219
Gharat, S. A., Momin, M., & Bhavsar, C. (2016) · Critical Reviews™ in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2016016272 · Cited by 220
Wang, H., Agarwal, P., Zhao, S., Xu, R. X., Yu, J., Lu, X., & He, X. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.08.048 · Cited by 218
“As the positive surface charge of nanoparticles might interact with blood proteins to reduce the efficiency of in vivo drug delivery [38], the nanoparticles synthesized using 0.”
MethodWani, W. A., Prashar, S., Shreaz, S., & Gómez-Ruiz, S. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.01.001 · Cited by 218
Liu, Y., Qiao, L., Zhang, S., Wan, G., Chen, B., Zhou, P., Zhang, N., & Wang, Y. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.11.010 · Cited by 218
“Different drugs can be coloaded into a single nanocarrier system and co-delivered efficiently to the tumor through the enhanced permeability and retention (EPR) effect, and/or the active tumor-targeting effect; thus, this delivery mode is very favorable for exerting synergistic effects of these drugs [5,6].”
Background
Metadata
- Authors
- Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y.
- Affiliations
- Georgia Institute of Technology (US)
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2014-10-07
- Volume
- 53
- Issue
- 46
- Pages
- 12320-12364
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2134726513
- Cited by
- 2,164
- References
- 578
- Citations by year
- 2026: 57 · 2025: 146 · 2024: 163 · 2023: 153 · 2022: 209 · 2021: 200 · 2020: 221 · 2019: 237 · 2018: 257 · 2017: 230 · 2016: 180 · 2015: 109 · 2014: 2
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- engineered nanoparticles, drug delivery, cancer therapy, targeted drug delivery, enhanced permeability and retention effect, pH-responsive delivery, tumor-targeting ligands, tissue distribution, circulation half-life, immunogenicity, combination therapy, multidrug resistance, contrast media, theranostics, nanoparticle surface modification
- MeSH terms
- Animals, Antineoplastic Agents, Delayed-Action Preparations, Humans, Neoplasms, Drug Delivery Systems, Nanotechnology, Nanomedicine, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.